Tumorprokoagulans, Gerinnung und Fibrinolyse bei malignen Erkrankungen

Zusammenfassung

Es muß betont werden, daß das Gerinnungssystem einschließlich der Ablagerung und Auflösung von Fibrin wahrscheinlich eine bedeutende Rolle bei der Tumorkrankheit spielt. Beim Tumorprokoagulans handelt es sich um eine Zystein-Proteinase maligner Zellen, die die Gerinnung zu aktivieren vermag und somit eine Rolle bei der Hyperaktivität des Gerinnungssystems bei Tumorkranken spielen könnte.

• Literatur

• 1 Trousseau A. Clinique Medicale de l’Hotel-dieu de Paris. 5th. edition, 3: 94 J. B. Bailliere et Fils; Paris: 1865
• 2 Fischer A. Arch. Entwicklungsmech. Org. 104: 210-219 1925;
• 3 Lieberman J. S, Borrero J, Urdaneta E, Wright I. S. Thrombophlebitis and cancer. JAMA. 177: 542 1961;
• 4 Nusbacher J. Migratory venous thrombosis and cancer. N. Y. State J. Med. 64: 2166 1964;
• 5 Warren B. A. Tumor metastasis and thrombosis. Thrombosis: Pathogenesis and clinical trials. Proc. Int. Comm, on Thromb. and Haemostasis, Vienna, Austria, June 18 to 23, 1973: 139.
• 6 Soong B. C. F, Miller S. O. Coagulation disorders in cancer. III. Fibrinolysis and inhibitors. Cancer 25: 867-873 1970;
• 7 Astrup T, Mullertz B. The fibrin plate method for estimation of fibrinolytic activity. Arch. Biochem 40: 346 1952;
• 8 Cliffton E. E, Grossi C. E. Fibrin activity of human tumors as measured to fibrin plate method. Cancer. 08: 1146 1955;
• 9 Ossowski L, Unkeless J. C, Tobia A, Quigley J. P, Rifkin D. B, Reich E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Mammalian fibroblast cultures transformed by DNA and RNA tumor viruses. J. Exp. Med. 137: 112-126 1973;
• 10 Hisazumi H. Inhibitory effect of normal and cancerous tissues of the bladder on plasminogen activation. Invest. Urology II: 258-262 1973;
• 11 Christman J. K, Silverstein S. C, Asc G. Plasminogen activators. In: Barrett A. (Ed.): Proteinases in Mammalian Cells and Tissues. Elsevier, Amsterdam; 1977: 827-839.
• 12 Moscatell D, Rifkin D, Isseroff R. R, Jaffe E. A. Plasminogen activator, plasmin, and collagenase interactions. Proteinases and Tumor Invasion 06: 143-152 1980;
• 13 Duffy M. J, O’Grady P. Plasminogen activator and cancer. Eur. J. Cancer Clin. Oncol. 20: 577-582 1984;
• 14 Ossowski L, Quigley J. P, Reich E. Fibrinolysis associated with oncogenic transformation. J. Bio. Chem. 249: 4312-4320 1974;
• 15 Ossowski L, Quigley J. P, Kellerman G. M, Reich E. Fibrinolysis associated with oncogenic transformation. J. Exp. Med. 138: 1056-1064 1973;
• 16 Unkeless J, Dan K, Kellerman G. M, Reich E. Fibrinolysis associate with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator. J. Biol. Chem. 249: 4295 1974;
• 17 Unkeless J. C, Tobia A, Ossowski L, Quigley J. P, Rifkin D. G, Reich E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. chick embryo fibroblast cultures transformed by Avian RNA tumor viruses. J. Exp. Med. 137: 85-111 1973;
• 18 Collen D. On the regulation and control of fibrinolysis. Kowalski E. Memorial Lecture. Presented at VIIth Internatl. Congress on Thrombosis and Haemostasis; July 15-20 1979
• 19 Mattsson C, Nyberg-Arrhenius V, Wallen P. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system. Throm. Res. 21: 535-545 1981;
• 20 Radcliffe R, Heinze T. Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator? Arch. Biochem. Biophys. 211: 750-761 1981;
• 21 Shyamala S, Dickerman I. I. Two types of plasminogen activators secreted by MCF 7 cells. Biochem. Biophys. Res. Commun 105: 1597-1603 1982;
• 22 Mott D. M, Fabisch P. H, Sani B. P, Sorof S. Lack of correlation between fibrinolysis and the transformed state of cultured mammalian cells. Biochem. Biophys. Res. Comm. 61: 571 1974;
• 23 Astrup T. Plasminogen activator from normal cells at various phases of the cell cycle. Cold Springs Harbor Symposium. 1974
• 24 Chen L. B, Buchanan J. M. Plasminogenindependent fibrinolysis by proteases produced by transformed chick embryo fibroblasts. Proc. Nat. Acad. Sci. 72 (03) 1132 1974;
• 25 O’Grady R. I, Upfold L. I, Stephens R. W. Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. Int. J. Cancer 28: 509-515 1981;
• 26 Kodama Y, Tanaka K. Effects of urokinase on growth and metastasis of rabbit V2 carcinoma. Gann 69: 9-15 1978;
• 27 Evers J. L, Patel J, Madeja J. et al. Plasminogen activator activity and composition in human breast cancer. Cancer Res. 42: 219-226 1982;
• 28 Blumberg P. M, Robbins P. W. Effect of proteases on activation of resting embryo fibroblasts and on cell surface proteins. Cell. 06: 137-147 1975;
• 29 Ossowski L, Quigley J. P, Reich E. Plasminogen a necessary factor for cell migration in vitro. In: Reich E, Rifkin D. B, Shaw E. (Eds.): Proteases and Biological Control. Cold Spring Harbor Laboratory; New York: 1975: 901-913.
• 30 Hynes R. O. Alteration of cell surface proteins by viral transformation and by proteolysis. Proc. Natl. Acad. Sci. 11: 3170-3171 1973;
• 31 Schleuning W. D, Granelli-Piperno A. Plasminogen activator from cultured cells and from plasma. In: Holzer H, Tschesche H. (Eds.): Biological Functions of Proteinases. Springer; Berlin: 1979: 171-185.
• 32 Ambrus J. L, Ambrus C. M, Pickern J, Soldes S, Bross I. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J. Med. 06: 433-458 1975;
• 33 Kasimis B. S, Spiers A. D. Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 1159 1979;
• 34 Rickles F. R, Edwards R. L. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62: 14-31 1983;
• 35 Hiramoto R, Bernecky J, Jurandowski J, Pressman D. Fibrin in human tumors. Cancer Res 20: 592 1960;
• 36 Franks J. J, Gordon S. G, Kao B, Sullivan T, Kirch D. Increased fibrin formation with tumors and its genesis. In: Plasma Protein Turnover. Blanchi R, Mariani G, McFarlane A. S. (Eds.). MacMillan, Basing Stoke; 1976: 423-440.
• 37 Dvorak H. F, Orenstein N. S, Carvalho A. C, Churchill W. H, Dvorak A. M, Galli S. J, Feder J, Bitzer A. M, Rypysc J, Giovinco P. Induction of a fibringel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122: 166-174 1979;
• 38 Dewey W. C, Bale W. F, Rose R. B, Marrack D. Localization of antifibrin antibodies in human tumors. Acta Unio Int. Cancer 19: 185 1963;
• 39 Ogura T, Tsubura E, Yamamura Y. Localization of radioiodinated fibrinogen in invaded and metastasized tumor tissue of Walker carcinosarcoma. GANN. 61: 443 1970;
• 40 O’Meara R. A. Q, Jackson R. D. Cytological observations on carcinoma. Irish J. Med. Sci. 391: 327 1958;
• 41 Donati M. B, Poggi A, Semeraro N. Coagulation and malignancy. In: Poller L. (Ed.): Recent Advances in Blood Coagulation. Vol. 3. Churchill Livingstone, Edinburgh; 1981: 227-259.
• 42 Wood Jr. S. Experimental studies on the spread of cancer with special reference to fibrinolytic agents and anticoagulants. J. Med. 05: 7-22 1974;
• 43 Goodall C. M, Saunders A. G, Shubik P. Studies of vascular patterns in living tumors with a transparent chamber inserted in hamster cheek pouch. J. Natl. Cancer Inst. 35: 497-521 1965;
• 44 Wood S, Strauli P. Tumor invasion and metastasis. In: The Pathogenesis of Cancer. Gregory J. E. (Ed.) Fremont Foundation, Pasedena; California: 1955: 140-151.
• 45 Wood Jr. S. Experimental studies of the intravascular dissemination of ascitic V2 carcinoma cells in the rabbit with special reference to fibrinogen and fibrinolytic agents. Bull. Swiss Acad. Med. Sci. 20: 92 1964;
• 46 Kinjo M. Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study. Brit. J. Cancer 38: 293 1978;
• 47 Millar R. C, Ketcham A. S. The effect of heparin and warfarin on primary and metastatic tumors. J. Med. 05: 23-31 1974;
• 48 Elias E. G. Heparin anticoagulation as adjuvant to chemotherapy in carcinoma of the lung. J. Med. 05: 114-132 1974;
• 49 Thornes R. D. Warfarin as maintenance therapy for cancer. J. Irish Coll. Phys. Surg. 02: 41-42 1972;
• 50 Hilgard P, Maat B. Mechanisms of lung tumor colony reduction caused by coumarin anticoagulation. Eur. J. Cancer 15: 183-187 1979;
• 51 Colucci M, Giavazzi R, Alessandri G, Semeraro N, Mantovani A, Donati M. D. Procoagulant activity of sarcoma sublines with different metastatic potential. Blood 57: 733-735 1981;
• 52 Gorelik E, Bere W. W, Herberman R. B. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int. J. Cancer. 33: 87 1984;
• 53 Peterson H, Zettergran L. Thromboplastin and fibrinolytic properties of three transplantable rat tumors. Acta Chir. Scand. 136: 365 1970;
• 54 Boggust W. A, O’Brien D. J, O’Meara R. A. Q, Thornes R. D. The coagulative factors of normal human and human cancer tissue. Irish J. Med. Sci. 477: 131 1963;
• 55 Pineo G. F, Regoeczi E, Hatton M. W. C, Brain M. C. The activation of coagulation by extracts of mucus : a possible ‘ pathway of intravascular coagulation accompanying adenocarcinomas. J. Lab. Clin. Med. 82: 255 1973;
• 56 Holyoke E. D, Frank A. L, Weiss L. Tumor thromboplastin activity in vitro. Int. J. Cancer 09: 258 1972;
• 57 Khato J, Suzuki M, Sato H. Quantitative study on thromboplastin in various strains of Yoshida ascites hepatoma cells of rat. GANN. 65: 289 1974;
• 58 Maynard J. R, Fintel D. J, Pitlick F. A, Nemerson Y. Tissue factor in cultured cells: pharmacologic effects. Lab. Invest. 35: 550-556 1976;
• 59 Jesty J, Spencer A. K, Nemerson Y. The mechanism of activation of factor X. J. Biol. Chem. 249: 5614 1974;
• 60 Nemerson Y, Bach R. Tissue factor revisited. Hemos. Thromb. 06: 237-261 1982;
• 61 Bach R, Nemerson Y, Königsberg W. Purification and characterization of bovine tissue factor. J. Biol. Chem. 256: 8324-8331 1981;
• 62 Garg S. K, Niemetz J. Tissue factor activity of normal and leukemic cells. Blood 42: 729-735 1973;
• 63 Khato J, Suzuki M, Sato H. Quantitative study on thromboplastin in various strains of Yoshida ascites hepatome cells of rat. GANN. 65: 284-294 1974;
• 64 Hudig D, Rapaport S. I, Bajaj S. P. Tissue factor-like activity of the human monocyte tumor cell line U937. Thromb. Res. 27: 321-332 1982;
• 65 Curatolo L, eAlessio G, Gambacorti C, Casali A, Morasca L, Semeraro N, Donati M. B. Procoagulant activity of mouse and human cultured cells following various types of transformation. Int. J. Cancer 35: 411-414 1985;
• 66 Nemerson Y, Clyne L. P. An assay for coagulation factor VII using factor VII-depleted bovine plasma. J. Lab. Clin. Med. 83 (02) 301 1974;
• 67 Gordon S. G, Franks J. J, Lewis B. Cancer procoagulant A: A factor X activating procoagulant from malignant tissue. Thrombos. Res. 06: 127-135 1975;
• 68 Gordon S. G, Cross B. A. A factor X activating cysteine protease from malignant tissue. J. Clin. Invest. 67: 1665-1671 1981;
• 69 Gordon S. G. A proteolytic procoagulant associated with malignant transformation. J. Histochem. Cytochem 29: 457 1981;
• 70 Falanga A, Gordon S. G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochem.. 1985 (in press).
• 71 Bajaj S. P, Rappaport S. I, Brown S. F. Isolation and characterization of human factor VII. J. Biol. Chem. 256: 253-259 1981;
• 72 Broze G. J, Majerus P. W. Purification and properties of human coagulation factor VII. J. Biol. Chem. 255: 1242-1247 1980;
• 73 Osterud B, Bouma B. N, Griffin J. H. Human blood coagulation factor IX. J. Biol. Chem. 253: 5946-5951 1978;
• 74 Gordon S. G, Hashiba U, Cross B. A, Poole M. A, Falanga A. A Cysteine proteinase procoagulant from amnionchorion. Blood. 1985 (in press).
• 75 Falanga A, Gordon S. G. Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant. Biochim. Biophys. Acta. 1985 (in press).
• 76 Gordon S. G, Lewis B. J. Comparison of procoagulant from normal and transformed fibroblasts. Cancer Res. 38: 2467-2472 1978;
• 77 Gordon S. G, Franks J. J, Lewis B. J. Comparison of procoagulants in extracts of normal and malignant human tissue. J. Natl. Cancer Inst. 62: 773-776 1979;
• 78 Gordon S. G, Gilbert L. C, Lewis B. J. Analysis of procoagulant activity of intact cells from tissue culture. Thromb. Res. 26: 379-387 1982;
• 79 Gordon S. G, Cross B. A. Cancer procoagulant immunoassay as a cancer detection antigen. Clin. Res. 32: 415 1984;
• 80 Gordon S. G, Cross B. A. An ELISA for cancer procoagulant as a tumor marker. (Submitted for publication, 1985)
• 81 Barrett A. J. Proteinases in Mammalian Cells and Tissues. Dingle J. T. (Ed.). Elsevier, Amsterdam; 1977: 181-208.